Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer? episode artwork

EPISODE · Nov 11, 2015 · 5 MIN

Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

from GRACEcast · host cancerGRACE Meetings

Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.

Episode metadata supplied by the publisher feed · Published Nov 11, 2015

Embed this episode

NOW PLAYING

Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

0:00 5:06

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 5 minutes long.

When was this GRACEcast episode published?

This episode was published on November 11, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!